Fatal or nonfatal myocardial infarction · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)
Antiplatelet agents probably leads to lower fatal or nonfatal myocardial infarction compared with control (moderate certainty).
1 finding from 1 review
Fatal or nonfatal stroke · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)
It is very uncertain whether antiplatelet agents changes fatal or nonfatal stroke compared with control (very low certainty).
1 finding from 1 review
Death (any cause) · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)
Antiplatelet agents showed no clear difference in death (any cause) compared with control (low certainty).
1 finding from 1 review
Cardiovascular mortality · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)
It is very uncertain whether antiplatelet agents changes cardiovascular death compared with control (very low certainty).
1 finding from 1 review
Major bleeding · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)
Antiplatelet agents probably leads to higher major bleeding compared with control (moderate certainty).
1 finding from 1 review
Minor bleeding · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)
Antiplatelet agents may leads to higher minor bleeding compared with control (low certainty).
1 finding from 1 review
Early access thrombosis (before 8 weeks) · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)
Antiplatelet agents may leads to lower early access thrombosis (before 8 weeks) compared with control (low certainty).
1 finding from 1 review